Compare NGL & TMDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NGL | TMDX |
|---|---|---|
| Founded | 1940 | 1998 |
| Country | United States | United States |
| Employees | 569 | N/A |
| Industry | Natural Gas Distribution | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 2.2B |
| IPO Year | N/A | 2019 |
| Metric | NGL | TMDX |
|---|---|---|
| Price | $18.31 | $68.76 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $148.22 |
| AVG Volume (30 Days) | 237.9K | ★ 1.7M |
| Earning Date | 05-28-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 382.18 |
| EPS | N/A | ★ 0.20 |
| Revenue | N/A | ★ $605,494,000.00 |
| Revenue This Year | N/A | $24.25 |
| Revenue Next Year | N/A | $18.75 |
| P/E Ratio | $366.01 | ★ $343.30 |
| Revenue Growth | N/A | ★ 37.13 |
| 52 Week Low | $3.10 | $60.11 |
| 52 Week High | $18.80 | $156.00 |
| Indicator | NGL | TMDX |
|---|---|---|
| Relative Strength Index (RSI) | 73.98 | 31.56 |
| Support Level | $9.28 | $60.11 |
| Resistance Level | N/A | $142.44 |
| Average True Range (ATR) | 0.99 | 4.65 |
| MACD | 0.02 | 0.48 |
| Stochastic Oscillator | 84.68 | 22.22 |
NGL Energy Partners LP is a USA-based firm that owns and operates a vertically integrated energy business. The company's operating segments include Crude Oil Logistics, Water Solutions, and Liquids Logistics. It operates crude oil Logistics, owns pipeline injection stations, and offers services for the treatment and disposal of wastewater generated from crude oil and natural gas production, as well as for the disposal of solids, such as tank bottoms and drilling fluids. The firm also supplies natural gas liquids to retailers, wholesalers, refiners, and petrochemical plants and sells propane and distillates.
TransMedics Group Inc is a commercial-stage medical technology company transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. It has developed the Organ Care System (OCS) to comprehensively address the limitations of cold storage. The OCS is a portable organ perfusion, optimization, and monitoring system that utilizes technology to replicate near-physiologic conditions for donor organs outside of the human body. The company has developed and is commercializing a proprietary system to preserve and deliver human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation.